Genetic variations in a PTEN/AKT/mTOR axis and prostate cancer risk in a Chinese population

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Chen, Jiawei ^a   Shao, Pengfei ^a   Cao, Qiang ^a   Li, Pu ^a   Li, Jie ^a   Cai, Hongzhou ^a   Zhu, Jian ^a   Wang, Meilin ^b   Zhang, Zhengdong ^b   Qin, Chao ^a   Yin, Changjun ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN KINASE B;

AGED; AKT GENE; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER RISK; CANCER STAGING; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CHINA; CHINESE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRINKING BEHAVIOR; FAMILY HISTORY; GENE; GENE FREQUENCY; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MTOR GENE; PROSTATE CANCER; PTEN GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CHINA; DEMOGRAPHY; DISEASE PROGRESSION; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RISK FACTORS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84864021921     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040817     Document Type: Article

References (53)

1. Jemal A, Siegel R, Xu J, Ward E, (2011) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
2. McCracken M, Olsen M, Chen MS Jr, Jemal A, Thun M, et al. (2007) Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities. CA Cancer J Clin 57: 190-205.
3. Damber JE, Aus G, (2008) Prostate cancer. Lancet 371: 1710-1721.
4. Dianat SS, Margreiter M, Eckersberger E, Finkelstein J, Kuehas F, et al. (2009) Gene polymorphisms and prostate cancer: the evidence. BJU Int 104: 1560-1572.
5. Shao P, Ding Q, Qin C, Wang M, Tang J, et al. (2011) Functional polymorphisms in cell death pathway genes FAS and FAS ligand and risk of prostate cancer in a Chinese population. Prostate 71: 1122-1130.
6. Xu B, Mi YY, Min ZC, Cheng G, Tong N, et al. (2011) p53 codon 72 increased biochemical recurrence risk after radical prostatectomy in a southern Chinese population. Urol Int 85: 401-405.
7. Zheng J, Liu F, Lin X, Wang X, Ding Q, et al. (2011) Predictive Performance of prostate cancer risk in Chinese men using 33 reported prostate cancer risk-associated SNPs. Prostate.
8. Liu LZ, Zhou XD, Qian G, Shi X, Fang J, et al. (2007) AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. Cancer Res 67: 6325-6332.
9. Faried LS, Faried A, Kanuma T, Aoki H, Sano T, et al. (2008) Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix: A potential biomarker and molecular target therapy. Mol Carcinog 47: 446-457.
10. Yang X, Fraser M, Moll UM, Basak A, Tsang BK, (2006) Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway. Cancer Res 66: 3126-3136.
11. Zhou BP, Hu MC, Miller SA, Yu Z, Xia W, et al. (2000) HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J Biol Chem 275: 8027-8031.
12. Chung J, Bachelder RE, Lipscomb EA, Shaw LM, Mercurio AM, (2002) Integrin (alpha 6 beta 4) regulation of eIF-4E activity and VEGF translation: a survival mechanism for carcinoma cells. J Cell Biol 158: 165-174.
13. Cui X, Zhang P, Deng W, Oesterreich S, Lu Y, et al. (2003) Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol 17: 575-588.
14. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, et al. (2008) An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68: 6084-6091.
15. Granville CA, Memmott RM, Gills JJ, Dennis PA, (2006) Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin Cancer Res 12: 679-689.
16. Manning BD, Cantley LC, (2007) AKT/PKB signaling: navigating downstream. Cell 129: 1261-1274.
17. Salmena L, Carracedo A, Pandolfi PP, (2008) Tenets of PTEN tumor suppression. Cell 133: 403-414.
18. Chen YL, Law PY, Loh HH, (2005) Inhibition of PI3K/Akt signaling: an emerging paradigm for targeted cancer therapy. Curr Med Chem Anticancer Agents 5: 575-589.
19. Nicholson KM, Anderson NG, (2002) The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 14: 381-395.
20. Hartmann W, Kuchler J, Koch A, Friedrichs N, Waha A, et al. (2009) Activation of phosphatidylinositol-3′-kinase/AKT signaling is essential in hepatoblastoma survival. Clin Cancer Res 15: 4538-4545.
21. Faried LS, Faried A, Kanuma T, Sano T, Nakazato T, et al. (2006) Predictive and prognostic role of activated mammalian target of rapamycin in cervical cancer treated with cisplatin-based neoadjuvant chemotherapy. Oncol Rep 16: 57-63.
22. Lee S, Choi EJ, Jin C, Kim DH, (2005) Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol 97: 26-34.
23. Hou G, Xue L, Lu Z, Fan T, Tian F, et al. (2007) An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR. Cancer Lett 253: 236-248.
24. Wu X, Obata T, Khan Q, Highshaw RA, De Vere White R, et al. (2004) The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion. BJU Int 93: 143-150.
25. Wu L, Birle DC, Tannock IF, (2005) Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res 65: 2825-2831.
26. Kim JG, Chae YS, Sohn SK, Kang BW, Moon JH, et al. (2011) Clinical significance of genetic variations in the PI3K/PTEN/AKT/mTOR pathway in Korean patients with colorectal cancer. Oncology 79: 278-282.
27. Chen M, Gu J, Delclos GL, Killary AM, Fan Z, et al. (2010) Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients. Carcinogenesis 31: 1387-1391.
28. Chen M, Cassidy A, Gu J, Delclos GL, Zhen F, et al. (2009) Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk. Carcinogenesis 30: 2047-2052.
29. Lacey JV Jr, Yang H, Gaudet MM, Dunning A, Lissowska J, et al. (2011) Endometrial cancer and genetic variation in PTEN, PIK3CA, AKT1, MLH1, and MSH2 within a population-based case-control study. Gynecol Oncol 120: 167-173.
30. Slattery ML, Herrick JS, Lundgreen A, Fitzpatrick FA, Curtin K, et al. (2010) Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1. Carcinogenesis 31: 1604-1611.
31. Campa D, Husing A, Stein A, Dostal L, Boeing H, et al. (2011) Genetic variability of the mTOR pathway and prostate cancer risk in the European Prospective Investigation on Cancer (EPIC). PLoS One 6: e16914.
32. Bellacosa A, Kumar CC, Di Cristofano A, Testa JR, (2005) Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 94: 29-86.
33. Vogiatzi P, Cassone M, Claudio L, Claudio PP, (2009) Targeted therapy for advanced prostate cancer: Looking through new lenses. Drug News Perspect 22: 593-601.
34. Markman B, Dienstmann R, Tabernero J, (2010) Targeting the PI3K/Akt/mTOR pathway-beyond rapalogs. Oncotarget 1: 530-543.
35. Reinke A, Chen JC, Aronova S, Powers T, (2006) Caffeine targets TOR complex I and provides evidence for a regulatory link between the FRB and kinase domains of Tor1p. J Biol Chem 281: 31616-31626.
36. Urano J, Sato T, Matsuo T, Otsubo Y, Yamamoto M, et al. (2007) Point mutations in TOR confer Rheb-independent growth in fission yeast and nutrient-independent mammalian TOR signaling in mammalian cells. Proc Natl Acad Sci U S A 104: 3514-3519.
37. Ohne Y, Takahara T, Hatakeyama R, Matsuzaki T, Noda M, et al. (2008) Isolation of hyperactive mutants of mammalian target of rapamycin. J Biol Chem 283: 31861-31870.
38. Sato T, Nakashima A, Guo L, Coffman K, Tamanoi F, (2010) Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer. Oncogene 29: 2746-2752.
39. Sansal I, Sellers WR, (2004) The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 22: 2954-2963.
40. Kremer CL, Klein RR, Mendelson J, Browne W, Samadzedeh LK, et al. (2006) Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate 66: 1203-1212.
41. Liao Y, Grobholz R, Abel U, Trojan L, Michel MS, et al. (2003) Increase of AKT/PKB expression correlates with gleason pattern in human prostate cancer. Int J Cancer 107: 676-680.
42. Dai B, Kong YY, Ye DW, Ma CG, Zhou X, et al. (2009) Activation of the mammalian target of rapamycin signalling pathway in prostate cancer and its association with patient clinicopathological characteristics. BJU Int 104: 1009-1016.
43. Wang Y, Mikhailova M, Bose S, Pan CX, deVere White RW, et al. (2008) Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival. Oncogene 27: 7106-7117.
44. Gao H, Ouyang X, Banach-Petrosky WA, Gerald WL, Shen MM, et al. (2006) Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer. Proc Natl Acad Sci U S A 103: 14477-14482.
45. Gao N, Zhang Z, Jiang BH, Shi X, (2003) Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem Biophys Res Commun 310: 1124-1132.
46. Li J, Yen C, Liaw D, Podsypanina K, Bose S, et al. (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943-1947.
47. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, et al. (1997) Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15: 356-362.
48. Haiman CA, Stram DO, Cheng I, Giorgi EE, Pooler L, et al. (2006) Common genetic variation at PTEN and risk of sporadic breast and prostate cancer. Cancer Epidemiol Biomarkers Prev 15: 1021-1025.
49. Wang J, Lu Y, Koch AE, Zhang J, Taichman RS, (2008) CXCR6 induces prostate cancer progression by the AKT/mammalian target of rapamycin signaling pathway. Cancer Res 68: 10367-10376.
50. Shimizu Y, Segawa T, Inoue T, Shiraishi T, Yoshida T, et al. (2007) Increased Akt and phosphorylated Akt expression are associated with malignant biological features of prostate cancer in Japanese men. BJU Int 100: 685-690.
51. Malik SN, Brattain M, Ghosh PM, Troyer DA, Prihoda T, et al. (2002) Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 8: 1168-1171.
52. Bedolla R, Prihoda TJ, Kreisberg JI, Malik SN, Krishnegowda NK, et al. (2007) Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation. Clin Cancer Res 13: 3860-3867.
53. Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, et al. (2004) Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 64: 5232-5236.